1 atilotrelvir COVID-19 controlled studies, 1 RCTs
Supplementary Data — Atilotrelvir for COVID-19: real-time meta analysis of 1 study
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Lu (DB RCT) 13% 0.87 [0.77-0.99] no recov. 610 (n) 603 (n) Improvement, RR [CI] Treatment Control Lu (DB RCT) 25% 0.75 [0.66-0.86] viral+ 610 (n) 607 (n) Atilotrelvir COVID-19 outcomes c19 early .org November 2025 Favors atilotrelvir Favors control
Fig. S2. Comparison of results for RCTs versus observational studies.
For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
IMA and
WCH
provide treatment protocols.
Submit
